Amarin posts an­oth­er round of promis­ing car­dio out­comes da­ta for Vas­cepa. Cue more M&A chat­ter and ar­gu­ment

Build­ing on their first sur­pris­ing round of pos­i­tive car­dio re­sults for their in­dus­tri­al strength fish oil Vas­cepa, Amarin to­day out­lined a fresh set of da­ta that they hope to use to build a block­buster case for the drug by demon­strat­ing ex­tend­ed ben­e­fits that im­prove with time.

In an ex­plorato­ry analy­sis — trans­la­tion: some­thing that is im­me­di­ate­ly con­tro­ver­sial — their re­searchers in­volved in the RE­DUCE-IT study point­ed to a 30% re­duc­tion in car­dio­vas­cu­lar events com­pared to the place­bo arm. That would amount to a drop of 159 MACE events for every 1,000 high-risk pa­tients treat­ed over 5 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER